2024.10.01 (화)

  • 구름많음동두천 22.4℃
  • 구름많음강릉 23.7℃
  • 맑음서울 24.0℃
  • 구름많음대전 24.7℃
  • 구름많음대구 23.5℃
  • 구름조금울산 24.7℃
  • 구름많음광주 25.8℃
  • 구름조금부산 27.9℃
  • 구름조금고창 26.8℃
  • 구름조금제주 27.7℃
  • 구름조금강화 23.1℃
  • 구름많음보은 23.4℃
  • 구름많음금산 24.8℃
  • 구름많음강진군 25.9℃
  • 구름많음경주시 24.7℃
  • 맑음거제 25.1℃
기상청 제공

경제

OxOnc Announces Agreement With Pfizer to Develop Crizotinib as First-Line and Second-Line Treatment for Patients With ROS1-Positive Non-Small Cell Lung Cancer

[By NBC-1TV H. J Yook]OxOnc Development LP, (OxOnc), today announced that it has entered into a co-development agreement with Pfizer Inc., to conduct a pivotal clinical trial of Pfizer's crizotinib, marketed under the trademark Xalkori®, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring a ROS1 (c-ros) gene rearrangement (ROS1-positive). ROS1 is a receptor tyrosine kinase of the insulin receptor family.

The trial will be conducted at multiple sites in Japan, China, Taiwan and South Korea to assess the safety and efficacy of crizotinib in patients with ROS1-positive advanced NSCLC. Crizotinib is approved for the treatment of patients with ALK-positive advanced NSCLC in the U.S., EU1, Japan and other countries.

Under the terms of the agreement, OxOnc will provide funding and supervision for the trial, with the goal of generating the clinical data necessary for Pfizer to submit crizotinib for review by regulatory authorities for the treatment of advanced ROS1-positive NSCLC in the Asian region. If approved for this indication, OxOnc will be eligible to receive milestone payments from Pfizer. Additional terms were not disclosed.

“We are extremely pleased to collaborate with Pfizer and to support further clinical development of Xalkori® in NSCLC patents. It is gratifying to be involved in co-developing this innovative targeted therapy which exemplifies the future of oncology drug development,” said Wenn Sun, Ph.D., OxOnc's Managing Partner.

“Pfizer continues to establish innovative partnerships that extend the scale and scope of our oncology clinical development program,” said Garry Nicholson, president and general manager, Pfizer Oncology. “Xalkori® is a breakthrough medicine in our oncology portfolio which may hold potential for patients with ROS1-positive advanced NSCLC. Through our collaboration with OxOnc, we hope to explore the potential benefit that this important therapy may bring to this subset of lung cancer patients who are in need of additional treatment options.”



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너